Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Neratinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 known ✓ | P04626 | 19/20 | 1.00 |
| ▸ | EGFR known ✓ | P00533 | 19/20 | 1.00 |
| ▸ | ERBB4 known ✓ | Q15303 | 1/20 | 1.00 |
| ▸ | SRC | P12931 | 2/20 | 1.00 |
| ▸ | KDR | P35968 | 2/20 | 1.00 |
| ▸ | STK25 | O00506 | 1/20 | 1.00 |
| ▸ | MAP2K7 | O14733 | 1/20 | 1.00 |
| ▸ | CHEK1 | O14757 | 1/20 | 1.00 |
| ▸ | GAK | O14976 | 1/20 | 1.00 |
| ▸ | EPHB6 | O15197 | 1/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 1/20 | 1.00 |
| ▸ | MAP3K13 | O43283 | 1/20 | 1.00 |
| ▸ | NUAK1 | O60285 | 1/20 | 1.00 |
| ▸ | STK17B | O94768 | 1/20 | 1.00 |
| ▸ | STK10 | O94804 | 1/20 | 1.00 |
| ▸ | PRKD3 | O94806 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | MAP4K4 | O95819 | 1/20 | 1.00 |
| ▸ | CHEK2 | O96017 | 1/20 | 1.00 |
| ▸ | ABL1 | P00519 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Neratinib SCHEMBL29376313 | 1.00 | ERBB2 (1.00) | ERBB2EGFRSRCKDRSTK25 | |
| Neratinib SCHEMBL15163655 | 1.00 | ERBB2 (1.00) | ERBB2EGFRSRCKDRSTK25 | |
| Neratinib SCHEMBL29394766 | 1.00 | ERBB2 (1.00) | ERBB2EGFRSRCKDRSTK25 | |
| Neratinib SCHEMBL29801657 | 1.00 | ERBB2 (1.00) | ERBB2EGFRSRCKDRSTK25 | |
| Neratinib SCHEMBL15163654 | 1.00 | ERBB2 (1.00) | ERBB2EGFRSRCKDRSTK25 | |
| Neratinib SCHEMBL571762 | 1.00 | ERBB2 (1.00) | ERBB2EGFRSRCKDRSTK25 | |
| Neratinib SCHEMBL2385159 | 0.97 | ERBB2 (0.95) | ERBB2EGFRSRCKDRSTK25 | |
| Neratinib SCHEMBL22408867 | 0.97 | ERBB2 (0.95) | ERBB2EGFRSRCKDRSTK25 | |
| Neratinib SCHEMBL2180998 | 0.97 | ERBB2 (0.95) | ERBB2EGFRSRCKDRSTK25 | |
| Neratinib SCHEMBL2385190 | 0.97 | ERBB2 (0.95) | ERBB2EGFRSRCKDRSTK25 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 575 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260092046-A1 | MALEATE SALTS OF (E)-N-{4-[3-CHLORO-4-(2-PYRIDINYLMETHOXY)ANILINO]-3-CYANO-7-ETHOXY-6-QUINOLINYL}-4-(DIMETHYLAMINO)-2-BUTENAMIDE AND CRYSTALLINE FORMS THEREOF | WYETH LLC (US) | 2026-04-02 | — | — | US | claimed |
| EP-3730139-B1 | ANTINEOPLASTIC COMBINATIONS CONTAINING HKI-272 AND VINORELBINE | WYETH LLC (US) | 2023-08-16 | — | — | EP | claimed |
| US-20230201155-A1 | Antineoplastic Combinations with m-TOR Inhibitor, Trastuzumab and/or HKI-272 | WYETH LLC (US) | 2023-06-29 | — | — | US | claimed |
| US-20220354820-A1 | Antineoplastic Combinations with m-TOR Inhibitor, Trastuzumab and/or HKI-272 | WYETH LLC (US) | 2022-11-10 | — | — | US | claimed |
| CN-106822127-B | Lenalinib maleate and crystalline forms | 惠氏有限责任公司 | 2022-07-29 | — | — | CN | claimed |
| EP-3443961-B1 | ANTINEOPLASTIC COMBINATIONS CONTAINING HKI-272 AND VINORELBINE | WYETH LLC (US) | 2020-10-28 | — | — | EP | claimed |
| EP-3730139-A1 | ANTINEOPLASTIC COMBINATIONS CONTAINING HKI-272 AND VINORELBINE | Wyeth LLC (US) | 2020-10-28 | — | — | EP | claimed |
| US-10729672-B2 | Antineoplastic combinations with mTOR inhibitor, trastuzumab and/or HKI-272 | WYETH LLC (US) | 2020-08-04 | — | — | US | claimed |
| EP-2498751-B1 | COATED DRUG SPHEROIDS AND USES THEREOF FOR ELIMINATING OR REDUCING CONDITIONS SUCH AS EMESIS AND DIARRHEA | WYETH LLC (US) | 2019-04-03 | — | — | EP | claimed |
| EP-3443961-A1 | ANTINEOPLASTIC COMBINATIONS CONTAINING HKI-272 AND VINORELBINE | Wyeth LLC (US) | 2019-02-20 | — | — | EP | claimed |
| EP-1670473-A1 | SUBSTITUTED QUINOLINES AS PROTEIN TYROSINE KINASE ENZYME INHIBITORS | Wyeth a Corporation of the State of Delaware (US) | 2006-06-21 | — | — | EP | claimed |
| US-20060128793-A1 | Analogs of 17-hydroxywortmannin as P13K inhibitors | WYETH (US) | 2006-06-15 | — | — | US | claimed |
| WO-2006044453-A1 | ANALOGS OF 17-HYDROXYWORTMANNIN AS PI3K INHIBITORS | WYETH (US) | 2006-04-27 | — | — | WO | claimed |
| WO-2006042100-A2 | METHOD FOR THE TREATMENT OF POLYCYSTIC KIDNEY DISEASE | WYETH (US) | 2006-04-20 | — | — | WO | claimed |
| US-20060079515-A1 | Method for the treatment of polycystic kidney disease | WYETH (US) | 2006-04-13 | — | — | US | claimed |
| WO-2006015775-A2 | EGFR KINASE INHIBITOR COMBINATIONS FOR TREATING RESPIRATORY AND GASTROINTESTINAL DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-02-16 | — | — | WO | claimed |
| US-20060035893-A1 | Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-02-16 | — | — | US | claimed |
| WO-2005034955-A1 | SUBSTITUTED QUINOLINES AS PROTEIN TYROSINE KINASE ENZYME INHIBITORS | WYETH (US) | 2005-04-21 | — | — | WO | claimed |
| WO-2005028443-A2 | PROTEIN TYROSINE KINASE ENZYME INHIBITORS | WYETH A CORPORATION OF THE STATE OF DELAWARE, USA (US) | 2005-03-31 | — | — | WO | claimed |
| US-20050059678-A1 | Protein tyrosine kinase enzyme inhibitors | WYETH (US) | 2005-03-17 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128793-A1 | Analogs of 17-hydroxywortmannin as P13K inhibitors | STK17A, STK17B, HSD17B7 | ERBB2 3357/4885EGFR 3411/4885ERBB4 3506/4885 |
| US-20060079515-A1 | Method for the treatment of polycystic kidney disease | ERBB2, PKD2, EGFR | ERBB2 1/4885EGFR 3/4885ERBB4 7/4885 |
| US-20050059678-A1 | Protein tyrosine kinase enzyme inhibitors | ABL1, ERBB2, RET | ERBB2 2/4885EGFR 6/4885ERBB4 8/4885 |
| US-20260092046-A1 | MALEATE SALTS OF (E)-N-{4-[3-CHLORO-4-(2-PYRIDINYLMETHOXY)ANILINO]-3-CYANO-7-ETHOXY-6-QUINOLINYL}-4-(DIMETHYLAMINO)-2-BUTENAMIDE AND CRYSTALLINE FORMS THEREOF | EGFR, MET, ERBB2 | ERBB2 3/4885EGFR 1/4885ERBB4 6/4885 |
| US-20220354820-A1 | Antineoplastic Combinations with m-TOR Inhibitor, Trastuzumab and/or HKI-272 | RICTOR, MTOR, TFPI2 | ERBB2 19/4885EGFR 80/4885ERBB4 148/4885 |
| US-20230201155-A1 | Antineoplastic Combinations with m-TOR Inhibitor, Trastuzumab and/or HKI-272 | RICTOR, MTOR, TFPI2 | ERBB2 19/4885EGFR 80/4885ERBB4 148/4885 |
| US-10729672-B2 | Antineoplastic combinations with mTOR inhibitor, trastuzumab and/or HKI-272 | RICTOR, HK2, MTOR | ERBB2 13/4885EGFR 81/4885ERBB4 188/4885 |
| US-20060035893-A1 | Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders | BDKRB2, EDNRB, GRK5 | ERBB2 29/4885EGFR 53/4885ERBB4 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.